Echocardiogram: Complete Guide to Cardiac Ultrasound Modalities, Interpretation, and Clinical Uses — Cost, Top Hospitals & Success Rates | MyMedicPlus

Echocardiography — commonly called an echocardiogram or echo — is a cardiac imaging technique using high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It is the single most important non-invasive cardiac imaging tool in clinical practice, providing comprehensive evaluation of ventricular and atrial size and function, cardiac valve anatomy and haemodynamics, pericardial disease, and aortic root pathology — all without ionising radiation and at relatively low cost compared to cardiac MRI or CT.

The echocardiographic examination encompasses multiple interrogation techniques used systematically in each study. Two-dimensional (2D) echocardiography provides real-time cross-sectional images of cardiac chambers and structures from standardised acoustic windows. M-mode echocardiography plots the motion of cardiac structures against time, providing precise linear measurements of LV internal dimensions and wall thickness. Doppler echocardiography — in its pulse-wave (PW), continuous-wave (CW), colour flow, and tissue Doppler imaging (TDI) modes — characterises blood flow velocities and pressure gradients across valves, and assesses diastolic function through myocardial tissue velocity analysis. Speckle-tracking echocardiography calculates global longitudinal strain (GLS), a sensitive marker of subclinical LV dysfunction increasingly used in cancer surveillance protocols. Stress echocardiography (exercise or pharmacological with dobutamine) unmasks ischaemia-induced wall motion abnormalities, assesses myocardial viability, and evaluates haemodynamically significant valve disease under physiological load. Transoesophageal echocardiography (TEE/TOE) uses a semi-invasive oesophageal probe for superior image quality in assessment of left atrial appendage thrombus, prosthetic valve function, aortic dissection, endocarditis vegetations, and guidance of transcatheter cardiac interventions.

Modern echocardiography provides a breadth of cardiac data that is unmatched by any single imaging modality — making it the foundation of cardiac assessment in acute and chronic heart failure, valve disease surveillance, cardiomyopathy evaluation, cancer cardiotoxicity monitoring, and critical care haemodynamic support.

Echocardiography is the investigation of choice across the full spectrum of structural and functional cardiac disease. Its clinical applications span urgent bedside assessment in haemodynamically unstable patients to serial long-term surveillance of chronic cardiac conditions.

Ventricular Function and Heart Failure

• Heart failure with reduced ejection fraction (HFrEF): LV ejection fraction (LVEF) below 40% by biplane Simpson's method. Echocardiography determines LV dilatation (LVIDd greater than 5.7 cm men, greater than 5.3 cm women), wall motion abnormality pattern (ischaemic — regional; non-ischaemic — global), and identifies correctable causes (mitral regurgitation, LV thrombus, tamponade).
• Heart failure with preserved ejection fraction (HFpEF): LVEF 50% or above with diastolic dysfunction. Graded by the ASE/EACVI 2016 algorithm using mitral inflow E/A ratio, septal and lateral TDI e', E/e' ratio, tricuspid regurgitation velocity (TR Vmax), and left atrial volume index (LAVI).
• Cardiomyopathies: Dilated (DCM — global LV dysfunction, LV dilatation), hypertrophic (HCM — asymmetric septal hypertrophy typically greater than 15 mm, LVOT obstruction assessed by CW Doppler — resting and Valsalva provoked gradient), restrictive (RCM — non-dilated, non-hypertrophied LV with diastolic filling pattern), arrhythmogenic right ventricular cardiomyopathy (ARVC — RV dilatation and dysfunction, regional RV wall motion abnormality).

Valvular Heart Disease

• Aortic stenosis: Graded by mean gradient (CW Doppler across aortic valve — severe: mean gradient greater than 40 mmHg) and aortic valve area (AVA) by continuity equation (severe: AVA less than 1.0 cm²). Modified Bernoulli equation: ΔP = 4V² (where V is the maximum jet velocity in m/s).
• Mitral regurgitation: Quantified by PISA (proximal isovelocity surface area) radius, vena contracta width (severe: VC greater than 7 mm), and effective regurgitant orifice area (EROA). Causes include myxomatous degeneration (Barlow disease), rheumatic, ischaemic (papillary muscle dysfunction), and functional (annular dilatation in DCM).
• Aortic and mitral stenosis: Mitral valve area (MVA) by planimetry or pressure half-time method (MVA = 220/PHT cm²).
• Endocarditis: Vegetation detection — TTE sensitivity 40–63%; TEE sensitivity 90–94%. Perivalvular complications (abscess, pseudoaneurysm, fistula) require TEE.

Pericardial Disease and Tamponade

Pericardial effusion is graded by depth — small (less than 10 mm), moderate (10–20 mm), large (greater than 20 mm). Cardiac tamponade is diagnosed echocardiographically by: right atrial free wall collapse (earliest sign — occurs in systole), right ventricular diastolic collapse, plethoric inferior vena cava (IVC greater than 2.1 cm with less than 50% inspiratory collapse), and respiratory variation in mitral and tricuspid inflow velocities greater than 25% (pulsus paradoxus equivalent).

Cancer Cardiotoxicity Surveillance

Echocardiography is the primary cardiac monitoring tool for patients receiving potentially cardiotoxic therapies — anthracyclines (doxorubicin), HER2-targeted agents (trastuzumab, pertuzumab), VEGF inhibitors, immune checkpoint inhibitors, and CAR-T cell therapy. GLS by speckle tracking is the recommended early marker of subclinical LV dysfunction (relative GLS reduction from baseline greater than 15% is clinically significant; absolute GLS more positive than -18% is concerning) before LVEF falls below 50%. Serial echocardiography before treatment initiation, after cycle 4, and at treatment completion is standard in oncology cardiology protocols.

Echocardiography is a broadly safe, non-invasive investigation requiring no ionising radiation and minimal patient preparation for standard transthoracic studies. Understanding appropriate indications helps ensure efficient use of the study and guides the correct echocardiographic modality selection.

Common Clinical Indications for Transthoracic Echocardiography (TTE)

• New or suspected heart failure (dyspnoea, oedema, reduced exercise tolerance)
• Evaluation of cardiac murmur for underlying valve pathology
• Chest pain evaluation — pericarditis, effusion, wall motion abnormality in ACS, aortic dissection
• Atrial fibrillation — LA size assessment, LV function, and valvular aetiology
• Stroke or TIA — cardiac source embolism evaluation (LA thrombus, PFO, tumour, valve vegetation)
• Hypertensive heart disease — LV hypertrophy grading, diastolic function
• Syncope — hypertrophic obstructive cardiomyopathy (HOCM), severe AS, cardiac tamponade exclusion
• Pre-operative cardiac assessment before major non-cardiac surgery in high-risk patients
• Cancer treatment cardiotoxicity baseline and surveillance (GLS-based protocol)
• Family screening for inherited cardiomyopathies (HCM, ARVC, Marfan syndrome aortic root)

Patient Preparation for TTE

Standard transthoracic echocardiography requires no fasting or bowel preparation. The patient changes into a gown and lies in the left lateral decubitus position for most views. Three ECG electrodes are attached to the chest to synchronise the cardiac cycle with image acquisition (ECG-gated imaging). The echocardiographer applies ultrasound gel to the transducer and the chest wall to eliminate the air interface. The study takes twenty to forty-five minutes depending on the complexity of findings.

Patient Preparation for Stress Echocardiography

Dobutamine stress echo (DSE) requires fasting for four hours before the procedure. Beta-blockers are typically withheld for 24–48 hours before DSE if the study is being performed to assess ischaemia (beta-blockers blunt the tachycardic response to dobutamine and reduce sensitivity). Patients should avoid caffeine on the day of the study. Exercise stress echo using a treadmill or bike requires the patient to be ambulatory and able to achieve at least 85% of age-predicted maximum heart rate. An IV cannula is placed before both DSE and exercise stress echo for emergency drug administration.

Patient Preparation for TOE/TEE

Transoesophageal echocardiography requires six hours of fasting (four hours clear liquids). Intravenous sedation (midazolam ± fentanyl) and throat spray (lidocaine 4% or 10%) are administered. Patients must have IV access and continuous monitoring throughout. A responsible adult escort is required for discharge as driving is not permitted for 12 hours post-sedation. Anticoagulation reversal before TOE is not routinely required for diagnostic studies.

A complete echocardiographic study integrates multiple interrogation modalities. Each provides complementary information about cardiac structure, haemodynamics, and tissue mechanics.

Standard 2D Views

Standard acoustic windows and views form the foundation of every echocardiogram. The parasternal long axis (PLAX) view images the left ventricle, mitral and aortic valves, aortic root, and left atrium simultaneously — the principal view for M-mode measurements. The parasternal short axis (PSAX) views at the aortic valve level (tricuspid aortic valve morphology, main pulmonary artery), mitral valve level (fish-mouth mitral valve opening, planimetry for MVA), and papillary muscle level (LV wall motion assessment) follow. Apical views — 4-chamber (A4C, all four chambers, mitral and tricuspid valves), 5-chamber (A5C, LVOT and aortic valve added), 2-chamber (A2C, LV inferior and anterior walls, mitral valve) — are used for Simpson's biplane LVEF, Doppler filling, and TDI. The subcostal 4-chamber view assesses the IVC (for CVP estimation and respiratory variation in tamponade) and provides an alternative window in patients with poor parasternal or apical windows (obesity, COPD, mechanical ventilation). The suprasternal notch view images the aortic arch and descending aorta (aortic coarctation, supravalvular stenosis).

M-Mode and LV Measurements

M-mode at the PLAX view measures LV internal diameter in diastole (LVIDd) and systole (LVIDs), interventricular septum thickness in diastole (IVSd), and posterior wall thickness (PWd). Normal LVIDd: 3.9–5.3 cm women, 4.2–5.9 cm men. The Teicholz formula (historically used for LVEF calculation from M-mode: EF = 7/(2.4 + D) x D³) has largely been superseded by the more accurate biplane Simpson's method for LVEF.

Biplane Simpson's Rule (Modified Method of Discs) for LVEF

The recommended method for LVEF by ASE/EACVI 2015 guidelines. The LV endocardium is traced at end-diastole and end-systole in both the A4C and A2C views. The software divides the LV into disc-shaped slices (modified Simpson's method) and sums their volumes: LVEDV (end-diastolic volume), LVESV (end-systolic volume). LVEF = (LVEDV - LVESV) / LVEDV x 100. Normal LVEF: 52–72% (women), 52–74% (men); mildly reduced 41–51%, moderately reduced 30–40%, severely reduced below 30%. Intraobserver and interobserver variability is 5–10%; serial measurements must account for this variation when assessing LVEF changes in cancer surveillance.

Global Longitudinal Strain (GLS) — Speckle Tracking

GLS is derived by tracking unique speckle patterns (formed by interference of backscattered ultrasound) frame-to-frame through the cardiac cycle in multiple apical views, generating a strain rate curve for each myocardial segment. Normal GLS is typically -20% to -22% (more negative = better deformation; the minus sign indicates shortening). A GLS more positive than -18% (less negative) suggests reduced longitudinal deformation and may indicate subclinical LV dysfunction before LVEF declines below 50%. In cancer cardiotoxicity surveillance, a relative reduction in GLS of greater than 15% from baseline is a clinically significant early warning requiring cardiology assessment and oncology discussion about cardioprotective therapy (ACE inhibitors, beta-blockers). GLS is more reproducible than LVEF for small serial changes and is the recommended monitoring parameter by the European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography (ASE) cardio-oncology guidelines.

Doppler Echocardiography

Pulse-wave (PW) Doppler: Samples flow velocity at a specific location (sample volume) in the heart or vessels. Used for mitral inflow (E wave — early passive filling velocity; A wave — late atrial contraction velocity; E/A ratio; deceleration time DT of E wave, normally 150–240 ms), LVOT velocity (VTI for stroke volume calculation: SV = LVOT cross-sectional area x LVOT VTI; cardiac output = SV x heart rate), and pulmonary vein flow. Continuous-wave (CW) Doppler: Measures the maximum velocity along the entire cursor beam — used for high-velocity jets across stenotic or regurgitant valves. The modified Bernoulli equation (ΔP = 4V²) converts peak velocity (m/s) to pressure gradient (mmHg). Severe aortic stenosis: peak velocity greater than 4 m/s, mean gradient greater than 40 mmHg by CW Doppler.

Tissue Doppler Imaging (TDI) and Diastolic Function Assessment

TDI uses low-velocity, high-amplitude Doppler signals to measure myocardial tissue velocity rather than blood velocity. Sampled at the septal and lateral mitral annulus, TDI provides: e' (early diastolic annular velocity — index of myocardial relaxation); a' (late diastolic velocity); s' (systolic velocity — correlates with LVEF). The E/e' ratio (mitral inflow E velocity divided by TDI annular e') estimates LV filling pressure (LV end-diastolic pressure, LVEDP). E/e' average (mean of septal and lateral) greater than 14, or lateral E/e' greater than 13, or septal E/e' greater than 15 indicates elevated LVEDP — a key criterion in the 2016 ASE/EACVI diastolic dysfunction grading algorithm. The four criteria for diastolic function grading: (1) average E/e' greater than 14; (2) septal e' less than 7 cm/s or lateral e' less than 10 cm/s; (3) TR velocity greater than 2.8 m/s (estimated RVSP); (4) LAVI greater than 34 mL/m². If 2 or more of 4 criteria are positive, diastolic dysfunction is present; more positive criteria indicate higher grade.

Colour Flow Doppler and Valve Regurgitation Assessment

Colour flow mapping overlays a colour-coded velocity display on the 2D image to visualise turbulent regurgitant jets and abnormal flow patterns. Valve regurgitation severity is quantified by: vena contracta (VC) width — the narrowest part of the regurgitant jet at the valve level (severe MR: VC greater than 7 mm; severe AR: VC greater than 6 mm); PISA (proximal isovelocity surface area) — a hemisphere of flow convergence on the ventricular side of the mitral valve (EROA = 2πr² x aliasing velocity / peak regurgitant velocity; severe MR: EROA greater than 0.4 cm²); jet area and length (qualitative, semi-quantitative for tricuspid and pulmonic regurgitation).

Aortic Valve Area by Continuity Equation

The continuity equation exploits conservation of mass to calculate AVA indirectly: AVA = (LVOT CSA x LVOT VTI) / AV VTI. LVOT cross-sectional area is calculated as πr² from the LVOT diameter measured in the PLAX view (typically 1.8–2.2 cm). LVOT VTI is obtained by PW Doppler, AV VTI by CW Doppler. Severe AS: AVA less than 1.0 cm² (indexed to BSA: AVA/BSA less than 0.6 cm²/m²). Reduced-flow, low-gradient severe AS (paradoxical low-flow AS) presents with AVA less than 1.0 cm² but mean gradient below 40 mmHg due to low stroke volume — requires dobutamine stress echo for haemodynamic reclassification.

Echocardiography holds a unique position in cardiac diagnostics because of its combination of real-time functional information, portability, absence of ionising radiation, low cost relative to MRI or CT, and dynamic physiological assessment capability (stress echo, Doppler haemodynamics).

Non-Invasive with No Ionising Radiation

Echocardiography uses sound waves — no ionising radiation is involved. This makes it safe for repeated serial assessment (cancer surveillance, heart failure monitoring, valve disease follow-up) without cumulative radiation exposure concerns. Pregnancy is not a contraindication. Contrast agents used in echocardiography (Definity, Optison — perflutren-based microbubble agents for LV opacification when 2 or more adjacent LV segments are not visualised) are non-nephrotoxic and are safe in renal impairment, unlike CT contrast agents or gadolinium for MRI.

Real-Time Functional Information Simultaneously with Structure

Echocardiography assesses chamber dimensions, wall motion, ejection fraction, valve morphology, and haemodynamic flow all in a single study — typically thirty to forty-five minutes. Cardiac MRI provides superior tissue characterisation (myocardial fibrosis by late gadolinium enhancement, cardiac iron quantification by T2*) but takes sixty to ninety minutes, is not portable, and cannot be used in patients with non-MRI-compatible devices (older pacemakers, cochlear implants). Echocardiography is the only bedside-deployable cardiac imaging tool, making it irreplaceable in acute settings.

Dynamic Physiological Assessment

Stress echocardiography provides information that no resting imaging modality can — specifically, the haemodynamic and wall motion response to cardiovascular stress. Dobutamine stress echo (DSE) at low doses (5–10 mcg/kg/min) identifies hibernating (viable, poorly contracting) myocardium by demonstrating the biphasic response: improved wall motion at low-dose dobutamine followed by deterioration at peak dose (ischaemic threshold). This information directly guides revascularisation decisions. Exercise stress echo uncovers provokable ischaemia in patients with stable angina where resting ECG and resting echo are normal. Stress echo with Doppler identifies mean gradient increase across the aortic valve on exercise — the haemodynamic correlate of functional symptom-generating AS.

TAPSE and RV Assessment

Tricuspid annular plane systolic excursion (TAPSE) is a simple M-mode measurement at the lateral tricuspid annulus, providing a reliable index of RV longitudinal systolic function. Normal TAPSE greater than 17 mm; TAPSE below 17 mm indicates reduced RV systolic function — clinically important in pulmonary hypertension, right heart failure, ARVC, and post-cardiac surgery RV dysfunction. Echocardiography provides comprehensive RV assessment including RV dimensions, systolic and diastolic function, tricuspid regurgitation-derived pulmonary artery systolic pressure (PASP = 4 x TR Vmax² + estimated RAP), and pericardial constraint — all inaccessible by CT without contrast or nuclear imaging.

Point-of-Care Echocardiography (POCUS) in Acute Settings

Portable ultrasound machines (Butterfly iQ+, Lumify, Vscan) enable physician-performed focused cardiac ultrasound at the bedside in emergency, intensive care, and resuscitation settings. The RACE (Rapid Assessment of Cardiac and Extracardiac structures) protocol in cardiac arrest integrates assessment of cardiac standstill versus preserved contractility, tamponade, RV strain (submassive/massive PE), and pneumothorax — all within sixty seconds of scan initiation. POCUS has transformed acute cardiac care by providing immediate answers about LV function, fluid responsiveness, and cardiac compressibility during resuscitation that guide real-time management decisions.

Transthoracic echocardiography (TTE) is one of the safest diagnostic investigations in medicine with an extremely low risk profile. Risks are more relevant to specialised modalities — stress echocardiography and transoesophageal echocardiography.

Risks of Standard Transthoracic Echocardiography

Standard TTE involves no risk beyond mild discomfort from the ultrasound probe on the chest wall, particularly over bony prominences. Contrast agents (perflutren microbubbles) carry a rare risk of anaphylactoid reactions (approximately 1 in 10,000) and are contraindicated in patients with right-to-left cardiac shunts (agitated saline bubble study is used for PFO detection instead). No ionising radiation is used. The study is completely non-invasive.

Risks of Dobutamine Stress Echocardiography (DSE)

• Arrhythmias: Dobutamine-induced tachyarrhythmias occur in 3–5% of studies; ventricular tachycardia requiring cardioversion in 0.08%; atrial fibrillation in 1–2%. Atropine is co-administered at low heart rate response to dobutamine to achieve target heart rate. Continuous ECG monitoring and resuscitation equipment including defibrillator are mandatory.
• Myocardial infarction: Occurs in less than 0.01% of DSE studies — equivalent to exercise treadmill testing. DSE is performed only with cardiology supervision and resuscitation capability.
• Hypertension or hypotension: Dobutamine causes positive chronotropy and inotropy; severe hypertension (systolic BP greater than 240 mmHg) or hypotension (fall more than 40 mmHg from baseline) are protocol stopping criteria.
• Absolute contraindications to DSE: Recent acute MI (within 5 days), unstable angina, haemodynamically significant arrhythmia, severe uncontrolled hypertension, known HOCM with significant LVOT obstruction (dobutamine provokes severe gradient increase and haemodynamic compromise), aortic aneurysm (mechanical stress risk).

Risks of Transoesophageal Echocardiography (TEE/TOE)

• Oesophageal perforation: The most serious complication; incidence approximately 1 in 10,000 procedures. Risk elevated with oesophageal stricture, Zenker's diverticulum, or malignancy. Oesophageal symptoms or history of dysphagia requires pre-procedure evaluation.
• Aspiration and laryngospasm: Managed with adequate throat anaesthesia, proper patient positioning (left lateral), and fasting compliance. Bite guard is used to protect the probe from patient biting.
• Dental injury: Oral trauma from probe manipulation in patients with vulnerable dentition.
• Sedation complications: Oxygen desaturation in 1–2% of TOE studies; managed with supplemental oxygen and sedation reversal agents.
• Contraindications to TOE: Oesophageal stricture, active oesophageal inflammation or surgery, oesophageal carcinoma, uncooperative patient, oropharyngeal pathology preventing probe introduction.

Technical Limitations

Acoustic window limitations (obesity, COPD, chest wall deformity, subcutaneous emphysema, mechanical ventilation) reduce image quality in 5–15% of patients. Contrast echo with LV opacification agents overcomes endocardial border definition problems in poor windows. TOE provides consistently superior image quality when transthoracic windows are inadequate. Cardiac MRI is the gold standard for structural assessment when echocardiographic image quality is insufficient for clinical decision-making.

Echocardiographic follow-up intervals are determined by the underlying diagnosis, the severity of findings, and any therapeutic interventions undertaken. Evidence-based surveillance guidelines from the ASE, EACVI, and ESC provide specific interval recommendations for common cardiac conditions.

Heart Failure Surveillance

Echocardiography is performed at diagnosis of heart failure and repeated in three to six months after initiating guideline-directed medical therapy (GDMT — ACE inhibitor/ARB/ARNI, beta-blocker, MRA, SGLT2 inhibitor) to document LV functional response. Patients with LFrEF who normalise LVEF (to 50% or above) on GDMT (termed HF with improved EF, HFimpEF) require ongoing annual echocardiographic surveillance, as LVEF may decline if GDMT is withdrawn. ICD and CRT device eligibility (LVEF at or below 35% after 3 months optimal GDMT) requires serial echocardiographic documentation before implantation.

Valvular Heart Disease Surveillance (ESC 2021 / AHA/ACC 2021 Guidelines)

• Severe aortic stenosis (AVA less than 1.0 cm²) — asymptomatic: Six-monthly echocardiogram to detect symptom development and LV functional decline (EF below 50% or fall greater than 10% is an indication for valve replacement in asymptomatic severe AS)
• Moderate aortic stenosis: One to two yearly echocardiogram
• Severe mitral regurgitation — asymptomatic: Six-monthly echo to detect LV dilatation (LVIDd greater than 40 mm/m² BSA) or EF decline (EF below 60% in primary MR) — both class I indications for surgery in asymptomatic patients
• Bicuspid aortic valve aortopathy: Annual echo for aortic root dimensions if diameter 4.0–4.5 cm; six-monthly if greater than 4.5 cm

Cancer Cardiotoxicity Surveillance (EACVI/ASE Cardio-Oncology Guidelines)

Anthracycline-based regimens: baseline echo before treatment; repeat after each 100 mg/m² cumulative doxorubicin dose for high-dose protocols; end-of-treatment echo; twelve-month post-treatment echo. HER2-targeted therapy (trastuzumab): baseline echo; repeat every three months during treatment; if significant LV dysfunction develops (LVEF fall greater than 10 percentage points to below 50%), hold trastuzumab and refer to cardiology. GLS should be included in all oncology surveillance echocardiograms as the earliest marker of subclinical cardiotoxicity.

Post-Procedure Echocardiography

Echo within 24–48 hours after transcatheter aortic valve implantation (TAVI/TAVR) assesses prosthesis position, paravalvular leak, LVEF recovery, and pericardial effusion. Echo after cardiac surgery (bypass grafting, valve repair/replacement) is performed before discharge and at six weeks post-operatively to assess valve function and LV recovery. TOE is used intraoperatively during cardiac surgery and transcatheter structural interventions (TAVI, MitraClip, LAA occlusion) for real-time procedural guidance.

Reporting and Normal Reference Ranges

Echocardiographic reports should quote LVEF by method, LV dimensions (LVIDd, LVIDs in cm), wall thickness (IVSd, PWd in mm), left atrial volume index (LAVI ml/m²; normal less than 34 mL/m²), diastolic function grade (if assessable), RVSP estimate (from TR velocity), and TAPSE. The Devereux formula calculates LV mass for LVH grading (indexed to BSA or height^2.7). All measurements should be referenced to BSA-indexed normal ranges from the ASE/EACVI 2015 chamber quantification guidelines.

Echocardiography costs vary considerably by modality (TTE vs stress echo vs TEE), healthcare system, and geographic region. Understanding cost structures helps patients plan investigations and navigate medical tourism options for elective cardiac assessment.

Approximate Echocardiography Costs by Modality and Region

• United States (TTE): USD 1,000–3,500 for a standard transthoracic echocardiogram including sonographer and cardiologist interpretation fees. With contrast agent (LV opacification): add USD 200–500. Medicare reimbursement for a complete 2D echo with Doppler (CPT 93306): approximately USD 400–700. Most private insurance covers echocardiography with appropriate clinical indication documentation.
• United States (stress echo — DSE or exercise): USD 1,500–4,500 including cardiologist supervision and interpretation; typically requires prior authorisation from insurers.
• United States (TEE): USD 1,500–4,000 including conscious sedation, cardiologist fee, and echocardiographer; facility fee additional.
• United Kingdom (NHS): Provided at no direct patient cost within the NHS referral pathway. Private TTE pricing: USD 300–800 at private cardiac diagnostic centres. Private stress echo: USD 600–1,200.
• India (JCI/NABH-accredited centres): TTE USD 30–100; stress echocardiography USD 80–250; TEE USD 120–350. Comprehensive echo with full Doppler, tissue Doppler, and GLS report is available at major Indian tertiary cardiac centres (Apollo, Fortis, Medanta, AIIMS) at 80-90% reduction versus US pricing. Cardiologist interpretation included in most packages.
• Thailand (private JCI hospitals): TTE USD 100–300; stress echo USD 200–600; TEE USD 300–700.
• Turkey: TTE USD 50–150; stress echo USD 150–400.

GLS (Speckle Tracking) and Advanced Echo Costing

Speckle-tracking GLS analysis requires dedicated software (EchoPAC, TomTec, AutoStrain) and adds technical time to the study. In Western markets, an echo with GLS may be billed separately or included in comprehensive cardio-oncology echo packages. In India and Thailand, GLS analysis is typically included in a comprehensive echocardiogram report without additional charge at major centres. Patients undergoing cancer cardiotoxicity surveillance echocardiography should specifically request GLS analysis in addition to standard LVEF reporting.

Medical Tourism Cardiac Workup Packages

Several major Indian and Thai hospitals offer cardiac health check packages including TTE, ECG, chest radiograph, and cardiologist consultation for USD 150–400 — equivalent in comprehensive content to investigations costing USD 3,000–6,000 in the United States. JCI accreditation of the echocardiography laboratory and cardiologist certification should be verified when choosing international cardiac diagnostic services. Digital echo reports and DICOM image files are provided for sharing with home country cardiologists.

While echocardiography is the first-line cardiac imaging investigation for the vast majority of clinical questions, complementary and alternative modalities provide information in specific contexts where echocardiography is technically limited or where additional tissue characterisation is required.

Cardiac MRI (CMR)

Cardiac MRI is the gold-standard reference modality for LV and RV volumes and ejection fraction (LVEF CMRI measurement variability is 3–5% vs 5–10% for echocardiography). CMR-specific capabilities include: late gadolinium enhancement (LGE) for myocardial fibrosis imaging — essential for diagnosis of cardiac sarcoidosis, cardiac amyloidosis (diffuse subendocardial LGE), hypertrophic cardiomyopathy (patchy mid-myocardial LGE), ARVC (fatty replacement), and myocarditis (intramyocardial or epicardial LGE); T2* mapping for myocardial iron quantification in thalassaemia and haemochromatosis; T1 mapping and extracellular volume (ECV) fraction for diffuse fibrosis quantification; aortic flow quantification by phase contrast. CMR is indicated when echocardiographic image quality is inadequate for clinical decision-making, and for fibrosis imaging not achievable by ultrasound. Limitations: longer scan time (60–90 minutes), cost (USD 1,500–4,000 in the US; USD 150–500 in India), inability to use in patients with non-MRI-compatible implanted devices, and unavailability at the bedside.

Cardiac CT (CCTA, Calcium Scoring)

Coronary CT angiography (CCTA) provides non-invasive anatomical assessment of coronary artery stenosis with a high negative predictive value (99%) for excluding obstructive coronary disease in low-to-intermediate risk chest pain. CT calcium scoring (Agatston score) is a preventive cardiology tool stratifying cardiovascular risk based on coronary artery calcium burden. CT aortography is preferred over echo for aortic aneurysm dimension measurement (CT provides reproducible external aortic diameter measurement without operator dependence). CT has the major limitation of ionising radiation (4–8 mSv for CCTA) — a concern for serial assessment in younger patients. CT cannot assess LV function in real time, diastolic function, or provide Doppler haemodynamics.

Nuclear Cardiology — SPECT and PET

Radionuclide myocardial perfusion imaging (MPI) by SPECT (Tc-99m sestamibi or tetrofosmin) assesses regional myocardial perfusion at rest and during pharmacological (adenosine, regadenoson) or exercise stress, identifying territories of ischaemia (reversible perfusion defect — viable, ischaemic) versus infarction (fixed perfusion defect — non-viable, scarred). SPECT MPI has a higher sensitivity for coronary artery disease than stress ECG alone. PET perfusion imaging (Rb-82 or N-13 ammonia) provides superior spatial resolution and absolute myocardial blood flow quantification — particularly valuable for microvascular coronary disease (INOCA — ischaemia with no obstructive coronary artery disease). Nuclear imaging involves significant radiation exposure (8–15 mSv for SPECT MPI) and is rarely used in patients who can be adequately assessed by stress echocardiography.

Invasive Coronary Angiography

Diagnostic catheterisation with coronary angiography (DCA) remains the gold standard for defining coronary anatomy when revascularisation planning is required. It is indicated after non-invasive stress testing documents significant ischaemia or after acute coronary syndrome for immediate anatomical assessment and potential percutaneous coronary intervention (PCI). Haemodynamic catheter assessment of LV filling pressures (LVEDP), cardiac output (Fick or thermodilution), and pulmonary artery pressures provides information complementary to echo-Doppler diastolic assessment and is indicated when non-invasive haemodynamic assessment is inconclusive for heart failure aetiology. Invasive assessment carries a 0.1–0.3% risk of serious complications (stroke, MI, death, access site bleeding).